Group 1: Company Performance and Market Outlook - The company anticipates a positive trend in performance following the recovery from the industry's low point since the 2023 medical sector restructuring, with a notable improvement in quarterly results [2] - The company has established a diversified product portfolio across four lines: ultrasound, endoscopy, surgery, and cardiovascular intervention, enhancing its competitive edge [2] - International business accounts for 50% of total revenue, indicating a strong global market presence and improved risk resilience [2] Group 2: Product Sales and Market Acceptance - The HD-650 endoscope has shown promising sales performance, with expectations for increased volume throughout the year, reflecting high clinical acceptance and competitive advantages [3] - The proportion of multi-scope configurations in orders from top-tier hospitals has increased, demonstrating the product's growing recognition in the market [3] Group 3: AI Integration in Medical Devices - The company employs over 30 dedicated R&D personnel in AI, focusing on enhancing ultrasound and endoscopy products with advanced functionalities [4] - AI applications in endoscopy include independent software for polyp detection and quality control, which significantly reduces the workload for frontline doctors [4] - In ultrasound, AI solutions have been developed for obstetrics and gynecology, improving diagnostic capabilities and clinical value [4] Group 4: Competitive Landscape and R&D Investment - The company views the influx of startups in the endoscopy sector as a challenge, citing high technical barriers and the lengthy process required for new products to gain clinical acceptance [5] - Continuous high-level investment in R&D allows the company to maintain its leading position in the endoscopy market and effectively compete against emerging players [5]